December 9, 2021
Life Sciences
  • The FDA authorized the first widely available drug to help prevent COVID-19 among people with vaccine allergies and those with weakened immune systems, for whom the shots may not be effective. The drug from AstraZeneca PLC is expected to offer longer-lasting protection than monoclonal antibody treatments given to high-risk COVID-19 patients. The Biden administration will buy up to 700,000 doses of the treatment. (Articles here, here, here, and here)